OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6. The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects. METHODS:Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days). Blood samples were obtained predose and up to 72 h postdose. RESULTS:Fourteen subjects completed both treatment arms. Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet. The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs). The t (max) was similar between the regimens. Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet. CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6. These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.
RCT Entities:
OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6. The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects. METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days). Blood samples were obtained predose and up to 72 h postdose. RESULTS: Fourteen subjects completed both treatment arms. Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet. The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs). The t (max) was similar between the regimens. Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet. CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6. These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.
Authors: Dolores M Shoback; John P Bilezikian; Stewart A Turner; Laura C McCary; Matthew D Guo; Munro Peacock Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: Michael H Skinner; Han-Yi Kuan; Alan Pan; Korbtham Sathirakul; Mary Pat Knadler; Celedon R Gonzales; Kwee Poo Yeo; Shobha Reddy; Maggie Lim; Mosun Ayan-Oshodi; Stephen D Wise Journal: Clin Pharmacol Ther Date: 2003-03 Impact factor: 6.875
Authors: Jill S Lindberg; Bruce Culleton; Gordon Wong; Michael F Borah; Roderick V Clark; Warren B Shapiro; Simon D Roger; Fred E Husserl; Preston S Klassen; Matthew D Guo; Moetaz B Albizem; Jack W Coburn Journal: J Am Soc Nephrol Date: 2005-02-02 Impact factor: 10.121
Authors: J Alderman; S H Preskorn; D J Greenblatt; W Harrison; D Penenberg; J Allison; M Chung Journal: J Clin Psychopharmacol Date: 1997-08 Impact factor: 3.153
Authors: Chaim Charytan; Jack W Coburn; Michel Chonchol; James Herman; Y Howard Lien; Wei Liu; Preston S Klassen; Laura C McCary; Vincent Pichette Journal: Am J Kidney Dis Date: 2005-07 Impact factor: 8.860
Authors: Geoffrey A Block; Kevin J Martin; Angel L M de Francisco; Stewart A Turner; Morrell M Avram; Michael G Suranyi; Gavril Hercz; John Cunningham; Ali K Abu-Alfa; Piergiorgio Messa; Daniel W Coyne; Francesco Locatelli; Raphael M Cohen; Pieter Evenepoel; Sharon M Moe; Albert Fournier; Johann Braun; Laura C McCary; Valter J Zani; Kurt A Olson; Tilman B Drüeke; William G Goodman Journal: N Engl J Med Date: 2004-04-08 Impact factor: 91.245
Authors: Walter Krauwinkel; James Dickinson; Marloes Schaddelee; John Meijer; Reiner Tretter; Jeroen van de Wetering; Gregory Strabach; Marcel van Gelderen Journal: Eur J Drug Metab Pharmacokinet Date: 2013-06-01 Impact factor: 2.441